文献速递乳腺MR

乳腺癌新辅助化疗后MRI预测病理完全缓解:按分子亚型分析

Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
PubMed 文献 · Eur Radiol · 2022-01-06

该研究纳入506例接受新辅助化疗后行MRI并手术的乳腺癌患者,由两名乳腺影像医师将MRI表现二分为影像学完全缓解与未完全缓解,评估MRI预测病理完全缓解的诊断效能。总体病理完全缓解率为30.04%,MRI预测准确率76.68%,且准确率随分子亚型不同而显著差异(p<0.001),激素受体阴性/人表皮生长因子受体2阳性型假阴性率最高(18.81%)。仅延迟期可见的细微强化与假阴性相关(76.2%,p=0.016)。

要点

  • MRI预测病理完全缓解的准确率因分子亚型而异(p<0.001),激素受体阴性/人表皮生长因子受体2阳性型假阴性率最高(18.81%)。
  • 仅延迟期可见的细微残余强化与假阴性病理完全缓解相关(76.2%,p=0.016)。
  • 新辅助化疗后MRI判读残余强化时,对细微且仅延迟期可见的强化需谨慎,避免过度诊断残余肿瘤。

核心结论

  • MRI预测病理完全缓解的诊断准确率因分子亚型不同而有差异;当新辅助化疗后MRI上残余强化细微且仅见于延迟期时,对残余肿瘤的过度解读应谨慎。

研究设计与样本

  • 研究纳入2018年1月至12月间接受新辅助化疗后行MRI并手术的506例乳腺癌患者,由两名乳腺影像医师将新辅助化疗后MRI表现二分为影像学完全缓解与未完全缓解,以最终病理报告为参考标准判定病理完全缓解,按激素受体和人表皮生长因子受体2状态分型,采用Pearson χ2检验和Wilcoxon秩和检验分析导致假阴性病理完全缓解的MRI表现。

关键影像表现/征象

  • 新辅助化疗后MRI残余病灶分为明显和细微两类,细微类进一步分类为结节状或延迟强化。
  • 仅延迟期可见的细微残余强化与假阴性病理完全缓解相关(76.2%,p=0.016)。

诊断标准与关键数值

  • 总体病理完全缓解率为30.04%。
  • MRI预测病理完全缓解的总体准确率为76.68%。
  • 各亚型准确率从高到低依次为:激素受体阴性/人表皮生长因子受体2阴性型85.63%、激素受体阳性/人表皮生长因子受体2阴性型82.84%、激素受体阳性/人表皮生长因子受体2阳性型69.37%、激素受体阴性/人表皮生长因子受体2阳性型62.38%,亚型间差异显著(p<0.001)。
  • 激素受体阴性/人表皮生长因子受体2阳性型MRI预测病理完全缓解的假阴性率最高(18.81%)。

临床应用与阅片要点

  • 阅片时需结合分子亚型评估MRI预测病理完全缓解的准确性,激素受体阴性/人表皮生长因子受体2阳性型假阴性率最高(18.81%)。
  • 报告新辅助化疗后MRI时,对细微且仅延迟期可见的残余强化应谨慎解读,避免过度诊断残余肿瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to investigate the predictability of breast MRI for pathologic complete response (pCR) by molecular subtype in patients with breast cancer receiving neoadjuvant chemotherapy (NAC) and investigate the MRI findings that can mimic residual malignancy.

METHODS: A total of 506 patients with breast cancer who underwent MRI after NAC and underwent surgery between January and December 2018 were included. Two breast radiologists dichotomized the post-NAC MRI findings as radiologic complete response (rCR) and no-rCR. The diagnostic performance of MRI predicting pCR was evaluated. pCR was determined based on the final pathology reports. Tumors were divided according to hormone receptor (HR) and human epidermal growth factor receptor (HER) 2. Residual lesions on post-NAC MRI were divided into overt and subtle which classified as nodularity or delayed enhancement. Pearson's χ2 and Wilcoxon rank-sum tests were used for MRI findings causing false-negative pCR.

RESULTS: The overall pCR rate was 30.04%. The overall accuracy for predicting pCR using MRI was 76.68%. The accuracy was significantly different by subtypes (p < 0.001), as follows in descending order: HR - /HER2 - (85.63%), HR + /HER2 - (82.84%), HR + /HER2 + (69.37%), and HR - /HER2 + (62.38%). MRI in the HR - /HER2 + type showed the highest false-negative rate (18.81%) for predicting pCR. The subtle residual enhancement observed only in the delayed phase was associated with false-negative findings (76.2%, p = 0.016).

CONCLUSIONS: The diagnostic accuracy of MRI for predicting pCR differed by molecular subtypes. When the residual enhancement on MRI after NAC is subtle and seen only in the delayed phase, overinterpretation of residual tumors should be performed with caution.

KEY POINTS: • In patients with breast cancer after completion of neoadjuvant chemotherapy, the diagnostic accuracy of MRI for predicting pathologic complete response (pCR) differed according to molecular subtype. • When residual enhancement on MRI is subtle and seen only in the delayed phase, this finding could be associated with false-negative pCR results.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim, Han, Ko, et al. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes. Eur Radiol. 2022. PMID: 34989844. doi:10.1007/s00330-021-08461-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。